- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Efanesoctocog Alfa prevents bleeding and improves QoL in patients with severe Hemophilia A: NEJM
USA: Once-weekly efanesoctocog alfa in patients with severe hemophilia A provides superior bleeding prevention to prestudy prophylaxis, according to results from a phase 3 study featured in the New England Journal of Medicine.
The treatment improved joint health, pain and physical health and provided normal to near-normal factor VIII activity.
Efanesoctocog alfa is known to provide high sustained factor VIII activity through overcoming the von Willebrand factor–imposed half-life ceiling. There is no clarity on the safety, efficacy, and pharmacokinetics of efanesoctocog alfa for treating and preventing bleeding episodes in previously treated patients with severe hemophilia A.
Annette von Drygalski, University of California in San Diego, and associates conducted a phase 3 study comprising patients with severe hemophilia A aged 12 and older. In group A, patients were assigned to once-weekly prophylaxis with efanesoctocog alfa for 52 weeks, 50 IU per kilogram of body weight. In group B, patients received on-demand efanesoctocog alfa treatment for 26 weeks, followed by once-weekly prophylaxis with efanesoctocog alfa for 26 weeks.
In group A, the mean annualized bleeding rate was determined (primary endpoint); an intrapatient comparison was made between the annualized bleeding rate during prophylaxis in group A and the rate during prestudy factor VIII prophylaxis (key secondary endpoint). Additional endpoints included safety, bleeding episodes, pharmacokinetics, changes in pain, joint health, and physical health.
The researchers reported the following findings:
- In group A comprising 133 patients, the median annualized bleeding rate was 0, and the estimated mean annualized bleeding rate was 0.71.
- There was a reduction in the mean annualized bleeding rate from 2.96 to 0.69, a finding that showed superiority over prestudy factor VIII prophylaxis.
- Group B comprised a total of 26 patients. One injection of efanesoctocog alfa in the overall population nearly resolved all bleeding episodes (97%).
- Efanesoctocog alfa's weekly prophylaxis provided mean factor VIII activity of above 40 IU per deciliter for most of the week and 15 IU per deciliter on day 7.
- Fifty-two weeks of prophylaxis with efanesoctocog alfa (group A) improved physical health, pain intensity, and joint health.
- Efanesoctocog alfa showed an acceptable side-effect profile in the overall study population, and there was no detection of the development of inhibitors to factor VIII.
"Our findings show that once-weekly efanesoctocog alfa, through maintaining high sustained factor VIII activity, provided substantial improvements in quality of life and clinical outcomes for patients with severe hemophilia A," the researchers conclude.
Reference:
Annette von Drygalski et al, Efanesoctocog Alfa Prophylaxis for Patients with Severe Hemophilia A, New England Journal of Medicine (2023). DOI: 10.1056/NEJMoa2209226
MSc. Biotechnology
Medha Baranwal joined Medical Dialogues as an Editor in 2018 for Speciality Medical Dialogues. She covers several medical specialties including Cardiac Sciences, Dentistry, Diabetes and Endo, Diagnostics, ENT, Gastroenterology, Neurosciences, and Radiology. She has completed her Bachelors in Biomedical Sciences from DU and then pursued Masters in Biotechnology from Amity University. She has a working experience of 5 years in the field of medical research writing, scientific writing, content writing, and content management. She can be contacted at  editorial@medicaldialogues.in. Contact no. 011-43720751
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751